Back to Home

RegenMed Investment Theses Webinar Recording Now Available

December 12, 2024

Share This Page
Facebook Logo
Twitter Logo
Linkedin Logo
Email Icon
View as PDF

RegenMed Investment Theses Webinar Recording Now Available

June 9, 2025

On November 12, RegenMed’s CEO and Co-Founder Michael P. Tierney conducted a webinar discussing the Company’s investment theses and global traction.  The webinar recording has been divided into ten chapters, now available on the Company’s Investors Page.

Share This Page
Facebook Logo
Twitter Logo
Linkedin Logo
Email Icon

RegenMed Investment Theses Webinar Recording Now Available

December 12, 2024

On November 12, RegenMed’s CEO and Co-Founder Michael P. Tierney conducted a webinar discussing the Company’s investment theses and global traction.  The webinar recording has been divided into ten chapters, now available on the Company’s Investors Page.

Share This Page
Facebook Logo
Twitter Logo
Linkedin Logo
Email Icon

Read The Latest

June 26, 2025

Invest in the Future: Webinar with Our CEO and Co-Founder

Discover the incredible growth potential of our company! Join our CEO and Co-Founder for insights into our $100B market opportunity, ongoing market traction, and future projections.

June 4, 2025

Advantages Of Circles Over "Big Data" RWE

Discover how Circles transform Big Data RWE by providing transparent, high-integrity insights directly from trusted sources. Say goodbye to fragmented, costly data and unlock meaningful, clinically relevant information while empowering physicians.

June 3, 2025

Peptides In Modern Medicine: Establishing Safety and Efficacy

Peptides are revolutionizing clinical diagnosis and treatment with their high selectivity and favorable side effect profiles. Here are some key insights:

RegenMed LLC Logo
Scroll Up Arrow

Equity crowdfunding investments in private placements, and start-up investments in particular, are speculative and involve a high degree of risk and those investors who cannot afford to lose their entire investment should not invest in start-ups. Companies seeking startup investment through equity crowdfunding tend to be in earlier stages of development and their business model, products and services may not yet be fully developed, operational or tested in the public marketplace. There is no guarantee that the stated valuation and other terms are accurate or in agreement with the market or industry valuations. Further, investors may receive illiquid and/or restricted stock that may be subject to holding period requirements and/or liquidity concerns.

Forward looking statements were included here that the Company believes to be accurate given the current information. They involve known and unknown risks, uncertainties and other important factors which if changed may affect the outcome(s).

DealMaker Securities LLC, a registered broker-dealer, and member of FINRA | SIPC, located at 4000 Eagle Point Corporate Drive, Suite 950, Birmingham, AL 35242., is the Intermediary for this offering and is not an affiliate of or connected with the Issuer.  Please check our background on FINRA's BrokerCheck.
DealMaker Securities LLC does not make investment recommendations.
DealMaker Securities LLC is NOT placing or selling these securities on behalf of the Issuer.
DealMaker Securities LLC is NOT soliciting this investment or making any recommendations by collecting, reviewing, and processing an Investor's documentation for this investment.
DealMaker Securities LLC conducts Anti-Money Laundering, Identity and Bad Actor Disqualification reviews of the Issuer, and confirms they are a registered business in good standing.
DealMaker Securities LLC is NOT vetting or approving the information provided by the Issuer or the Issuer itself.

Contact information is provided for Investors to make inquiries and requests to DealMaker Securities LLC regarding Regulation CF in general, or the status of such investor’s submitted documentation, specifically. DealMaker Securities LLC may direct Investors to specific sections of the Offering Circular to locate information or answers to their inquiry but does not opine or provide guidance on issuer related matters.

Copyright © 2025. RegenMed, Inc. All rights reserved.